Aten Porus Lifesciences

Business Model

Our business philosophy can be defined by what George Merck said, “We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.”

APL aims to discover and develop innovative medicines for diseases with a high unmet medical need. Our drug discovery efforts are guided by our business model of “Innovate and Incubate”. Novel biotech and drug discovery platforms are built into individual agile and nimble subsidiaries with their focus on broad disease areas with the underlying aim of developing breakthrough medicines.

Oraxion Therapeutics, Inc., (2016)

Orphan/Rare Diseases

Avammune Therapeutics (2019)

Immuno-oncology

Our Technology - Intellectual Property

APL is building and intellectual property portfolio to cover all aspects of the therapeutic modalities being developed. Our IP estate is designed to protect the chemistry, formulation and therapeutic application of the technology platform. The versatility of our technology platforms and IP portfolio allows us to partner with various groups with complementary expertise.

Chemisty

Design and Synthesis of Drug or Prodrug Claims.

Formulation

Formulation of Drug or Prodrug Claims.

Therapeutic Application

Method of Administration and Treatment Claims.

Leadership Team

Mr. Arun B Papaiah

Founder And Chief Executive Officer

Arun is the Founder and CEO at Aten Porus Lifesciences. He previously co-founded Avammune Therapeutics and Oraxion Therapeutics, R&D companies focused on drug discovery. Arun was instrumental in the option agreement of Oraxion’s technology platform to a US based biotech company for $125 MM.

Arun holds an MBA from the Royal Melbourne Institute of Technology (Australia), and a Bachelor of Science degree from Christ University (India). Arun has over 10 years of experience as an entrepreneur in various aspects of business including Finance, Operations, Technology transfer and Business development.

Dr. Aditya Kulkarni

Founder And Chief Scientific Officer

Aditya is the Founder and CSO at Aten Porus Lifesciences. He previously co-founded Avammune Therapeutics and Oraxion Therapeutics, R&D companies focused on drug discovery. Aditya is the inventor of Oraxion’s technology platform that was eventually licensed to a US based biotech company for $125 MM. He has co-authored >15 papers and filed several international patents in the areas of nucleic acid delivery, Niemann-Pick Type C therapeutics, and drug discovery.

He has been a recipient of scholarships during his Masters and PhD and was also awarded the H. C. Brown Award for Outstanding Organic Research at Purdue University in June 2012. Aditya has a PhD in Bioorganic Chemistry from Purdue University (USA), MS in Chemical Biology from Leeds University (UK), and B.Sc in Chemistry from Christ University (India).

Mr. Srinivasan Namala

Founder And Director

Srinivasan is the Founder and Director at Aten Porus Lifesciences. He previously co-founded Avammune Therapeutics and Oraxion Therapeutics, both R&D companies focusesd on drug discovery. He is currently serving as the CEO of Porus Labs, a chemical manufacturing conglomerate serving customers across India, US, and Europe.

Srinivasan has over 15 years of experience in varied aspects of business including technology transfer, SCM, Business Development and Finance. Srinivasan has an MS in Pharmaceutics from Northeastern University (USA), and B.Pharm from BITS Pilani (India).

About Us